Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa K Gilliam

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Diabetes Technology & Therapeutics|May 28, 2009
Practical aspects of real-time continuous glucose monitoringLisa K Gilliam, Irl B Hirsch
Diabetes Technology & Therapeutics|April 16, 2025
Dysglycemic Events after Initiation of Intermittently Scanned Continuous Glucose Monitoring in Patients with Insulin-Treated Type 2 DiabetesLisa K Gilliam, Melissa M Parker, Andrew J Karter
The Journal of Clinical Endocrinology and Metabolism|August 9, 2007
Tyramine-mediated activation of sympathetic nerves inhibits insulin secretion in humansLisa K Gilliam, Jerry P Palmer, Gerald J Taborsky
Acta Diabetologica|December 17, 2022
Quantification of risk factors for diabetic retinopathy progressionDariusz Tarasewicz, Carol Conell, Lisa K Gilliam, et al.
Diabetes|November 25, 2005
Autoantibodies in diabetesCatherine Pihoker, Lisa K Gilliam, Christiane S Hampe, et al.
International Journal of Circumpolar Health|May 11, 2002
Type 1 diabetes-related autoantibodies are rare in Alaska native populationsJustin Mohatt, Lisa K Gilliam, Lynn Bekris, et al.
Diabetes Technology & Therapeutics|August 3, 2023
Racial and Ethnic Differences in the Association Between Mean Glucose and Hemoglobin A1cAndrew J Karter, Melissa M Parker, Howard H Moffet, et al.
Journal of Immunological Methods|March 21, 2008
Antigen presentation of detergent-free glutamate decarboxylase (GAD65) is affected by human serum albumin as carrier proteinJordan Steed, Lisa K Gilliam, Robert A Harris, et al.
JAMA|June 2, 2021
Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated DiabetesAndrew J Karter, Melissa M Parker, Howard H Moffet, et al.
Diabetes Technology & Therapeutics|February 1, 2022
Continuous Glucose Monitor Use Prevents Glycemic Deterioration in Insulin-Treated Patients with Type 2 DiabetesAndrew J Karter, Melissa M Parker, Howard H Moffet, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Diabetes Technology & Therapeutics|May 28, 2009
Practical aspects of real-time continuous glucose monitoringLisa K Gilliam, Irl B Hirsch
Diabetes Technology & Therapeutics|April 16, 2025
Dysglycemic Events after Initiation of Intermittently Scanned Continuous Glucose Monitoring in Patients with Insulin-Treated Type 2 DiabetesLisa K Gilliam, Melissa M Parker, Andrew J Karter
The Journal of Clinical Endocrinology and Metabolism|August 9, 2007
Tyramine-mediated activation of sympathetic nerves inhibits insulin secretion in humansLisa K Gilliam, Jerry P Palmer, Gerald J Taborsky
Acta Diabetologica|December 17, 2022
Quantification of risk factors for diabetic retinopathy progressionDariusz Tarasewicz, Carol Conell, Lisa K Gilliam, et al.
Diabetes|November 25, 2005
Autoantibodies in diabetesCatherine Pihoker, Lisa K Gilliam, Christiane S Hampe, et al.
International Journal of Circumpolar Health|May 11, 2002
Type 1 diabetes-related autoantibodies are rare in Alaska native populationsJustin Mohatt, Lisa K Gilliam, Lynn Bekris, et al.
Diabetes Technology & Therapeutics|August 3, 2023
Racial and Ethnic Differences in the Association Between Mean Glucose and Hemoglobin A1cAndrew J Karter, Melissa M Parker, Howard H Moffet, et al.
Journal of Immunological Methods|March 21, 2008
Antigen presentation of detergent-free glutamate decarboxylase (GAD65) is affected by human serum albumin as carrier proteinJordan Steed, Lisa K Gilliam, Robert A Harris, et al.
JAMA|June 2, 2021
Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated DiabetesAndrew J Karter, Melissa M Parker, Howard H Moffet, et al.
Diabetes Technology & Therapeutics|February 1, 2022
Continuous Glucose Monitor Use Prevents Glycemic Deterioration in Insulin-Treated Patients with Type 2 DiabetesAndrew J Karter, Melissa M Parker, Howard H Moffet, et al.
Pageof 5